Prospects for Targeting PD-1 and PD-L1 in Various Tumor Types

被引：0

作者：

Kim, Joseph W. ^{[1
]}

Eder, Joseph Paul ^{[1
]}

机构：

[1] Yale Univ, Sch Med, Yale Comprehens Canc Ctr, Dept Med, New Haven, CT 06520 USA

来源：

ONCOLOGY-NEW YORK | 2014年 / 28卷

关键词：

RENAL-CELL CARCINOMA; CANCER; SAFETY; MELANOMA; SURVIVAL; ANTIBODY; IPILIMUMAB; ANTI-PD-1; EXPRESSION; REGRESSION;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Immune checkpoints, such as programmed death ligand 1 (PD-L1) or its receptor, programmed death 1 (PD-1), appear to be Achilles' heels for multiple tumor types. PD-L1 not only provides immune escape for tumor cells but also turns on the apoptosis switch on activated T cells. Therapies that block this interaction have demonstrated promising clinical activity in several tumor types. In this review, we will discuss the current status of several anti-PD-1 and anti-PD-L1 antibodies in clinical development and their direction for the future.

引用

页码：15 / 28

页数：14

共 50 条

[1] Relevance of host and tumor PD-L1 expression in PD-L1 and PD-1 blockade
Lin, Heng
Wei, Shuang
Vatan, Linda
Kryczek, Ilona
Zou, Weiping
JOURNAL OF IMMUNOLOGY, 2017, 198 (01):
[2] Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
Bai, Jie
Gao, Zhitao
Li, Xiang
Dong, Liang
Han, Weidong
Nie, Jing
ONCOTARGET, 2017, 8 (66) : 110693 - 110707
[3] Targeting the PD-1/PD-L1 interaction in nasopharyngeal carcinoma
Johnson, David
Ma, Brigette B. Y.
ORAL ONCOLOGY, 2021, 113
[4] Multispecific Antibodies Targeting PD-1/PD-L1 in Cancer
Chen, Miaomiao
Zhou, Yuli
Bao, Kaicheng
Chen, Siyu
Song, Guoqing
Wang, Siliang
BIODRUGS, 2025,
[5] Aptamers Targeting the PD-1/PD-L1 Axis: A Perspective
Bertrand, Philippe
JOURNAL OF MEDICINAL CHEMISTRY, 2023, 66 (16) : 10878 - 10888
[6] Targeting the PD-1/PD-L1 Axis in Human Vitiligo
Willemsen, Marcella
Melief, Cornelis J. M.
Bekkenk, Marcel W.
Luiten, Rosalie M.
FRONTIERS IN IMMUNOLOGY, 2020, 11
[7] Targeting PD-1/PD-L1 interactions for cancer immunotherapy
Zitvogel, Laurence
Kroemer, Guido
ONCOIMMUNOLOGY, 2012, 1 (08): : 1223 - 1225
[8] Targeting immune cell types of tumor microenvironment to overcome resistance to PD-1/PD-L1 blockade in lung cancer
Wang, Man
Zhu, Lijie
Yang, Xiaoxu
Li, Jiahui
Liu, Yu'e
Tang, Ying
FRONTIERS IN PHARMACOLOGY, 2023, 14
[9] Beyond inhibition against the PD-1/PD-L1 pathway: development of PD-L1 inhibitors targeting internalization and degradation of PD-L1
Guo, Jiazheng
Yu, Fengyi
Zhang, Kuojun
Jiang, Sheng
Zhang, Xiangyu
Wang, Tianyu
RSC MEDICINAL CHEMISTRY, 2024, 15 (04): : 1096 - 1108
[10] PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
Liu, Jinhua
Chen, Zichao
Li, Yaqun
Zhao, Wenjie
Wu, JiBiao
Zhang, Zhen
FRONTIERS IN PHARMACOLOGY, 2021, 12

← 1 2 3 4 5 →